Cholesterol lowering in intermediate-risk persons without cardiovascular disease
11 p.
- Autores:
-
Yusuf, Salim
Bosch, Jackie
Dagenais, Gilles
Zhu, Jun
Xavier, Denis
Liu, Lisheng
Pais, Prem
Lopez-Jaramillo, Patricio
Leiter, Lawrence A.
Dans, Antonio
Avezum, Alvaro
Piegas, Leopoldo S.
Parkhomenko, Alexander
Keltai, Katalin
Keltai, Matyas
Sliwa, Karen
Peters, Ron J.G.
Held, Claes
Chazova, Irina
Yusoff, Khalid
Lewis, Basil S.
Jansky, Petr
Khunti, Kamlesh
Toff, William D.
Reid, Christopher M.
Varigos, John
Sánchez Vallejo, Gregorio
McKelvie, Robert
Pogue, Janice
Jung, Hyejung
Gao, Peggy
Diaz, Rafael
Lonn, Eva
The HOPE-3 Investigators
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2016
- Institución:
- Universidad de Santander
- Repositorio:
- Repositorio Universidad de Santander
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.udes.edu.co:001/3459
- Acceso en línea:
- https://repositorio.udes.edu.co/handle/001/3459
- Palabra clave:
- Cholesterol lowering
Intermediate risk
Cardiovascular disease
- Rights
- openAccess
- License
- Derechos Reservados - New England Journal of Medicine, 2016
| id |
RUDES2_a5e09c3aafcb75880cf8374155e1e03c |
|---|---|
| oai_identifier_str |
oai:repositorio.udes.edu.co:001/3459 |
| network_acronym_str |
RUDES2 |
| network_name_str |
Repositorio Universidad de Santander |
| repository_id_str |
|
| dc.title.eng.fl_str_mv |
Cholesterol lowering in intermediate-risk persons without cardiovascular disease |
| title |
Cholesterol lowering in intermediate-risk persons without cardiovascular disease |
| spellingShingle |
Cholesterol lowering in intermediate-risk persons without cardiovascular disease Cholesterol lowering Intermediate risk Cardiovascular disease |
| title_short |
Cholesterol lowering in intermediate-risk persons without cardiovascular disease |
| title_full |
Cholesterol lowering in intermediate-risk persons without cardiovascular disease |
| title_fullStr |
Cholesterol lowering in intermediate-risk persons without cardiovascular disease |
| title_full_unstemmed |
Cholesterol lowering in intermediate-risk persons without cardiovascular disease |
| title_sort |
Cholesterol lowering in intermediate-risk persons without cardiovascular disease |
| dc.creator.fl_str_mv |
Yusuf, Salim Bosch, Jackie Dagenais, Gilles Zhu, Jun Xavier, Denis Liu, Lisheng Pais, Prem Lopez-Jaramillo, Patricio Leiter, Lawrence A. Dans, Antonio Avezum, Alvaro Piegas, Leopoldo S. Parkhomenko, Alexander Keltai, Katalin Keltai, Matyas Sliwa, Karen Peters, Ron J.G. Held, Claes Chazova, Irina Yusoff, Khalid Lewis, Basil S. Jansky, Petr Khunti, Kamlesh Toff, William D. Reid, Christopher M. Varigos, John Sánchez Vallejo, Gregorio McKelvie, Robert Pogue, Janice Jung, Hyejung Gao, Peggy Diaz, Rafael Lonn, Eva The HOPE-3 Investigators |
| dc.contributor.author.spa.fl_str_mv |
Yusuf, Salim Bosch, Jackie Dagenais, Gilles Zhu, Jun Xavier, Denis Liu, Lisheng Pais, Prem Lopez-Jaramillo, Patricio Leiter, Lawrence A. Dans, Antonio Avezum, Alvaro Piegas, Leopoldo S. Parkhomenko, Alexander Keltai, Katalin Keltai, Matyas Sliwa, Karen Peters, Ron J.G. Held, Claes Chazova, Irina Yusoff, Khalid Lewis, Basil S. Jansky, Petr Khunti, Kamlesh Toff, William D. Reid, Christopher M. Varigos, John Sánchez Vallejo, Gregorio McKelvie, Robert Pogue, Janice Jung, Hyejung Gao, Peggy Diaz, Rafael Lonn, Eva The HOPE-3 Investigators |
| dc.subject.proposal.eng.fl_str_mv |
Cholesterol lowering Intermediate risk Cardiovascular disease |
| topic |
Cholesterol lowering Intermediate risk Cardiovascular disease |
| description |
11 p. |
| publishDate |
2016 |
| dc.date.issued.spa.fl_str_mv |
2016-05-26 |
| dc.date.accessioned.spa.fl_str_mv |
2019-07-24T17:13:45Z |
| dc.date.available.spa.fl_str_mv |
2019-07-24T17:13:45Z |
| dc.type.spa.fl_str_mv |
Artículo de revista |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
| dc.type.content.spa.fl_str_mv |
Text |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/ART |
| dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
http://purl.org/coar/resource_type/c_6501 |
| status_str |
publishedVersion |
| dc.identifier.doi.spa.fl_str_mv |
10.1056/NEJMoa1600176 |
| dc.identifier.issn.spa.fl_str_mv |
1533-4406 0028-4793 |
| dc.identifier.uri.spa.fl_str_mv |
https://repositorio.udes.edu.co/handle/001/3459 |
| identifier_str_mv |
10.1056/NEJMoa1600176 1533-4406 0028-4793 |
| url |
https://repositorio.udes.edu.co/handle/001/3459 |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.relation.ispartof.eng.fl_str_mv |
New England Journal of Medicine |
| dc.rights.spa.fl_str_mv |
Derechos Reservados - New England Journal of Medicine, 2016 |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.creativecommons.spa.fl_str_mv |
Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) |
| dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc/4.0/ |
| rights_invalid_str_mv |
Derechos Reservados - New England Journal of Medicine, 2016 Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/ http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.source.eng.fl_str_mv |
https://pdfs.semanticscholar.org/fd2d/366541ea99b1b518b789b4456c65fe2c9913.pdf?_ga=2.266816654.1207694793.1563984236-1782380525.1556661431 |
| institution |
Universidad de Santander |
| bitstream.url.fl_str_mv |
https://repositorio.udes.edu.co/bitstreams/6a604cda-8879-45a8-b62c-f0510a013e1f/download https://repositorio.udes.edu.co/bitstreams/c1f0f371-7d30-41d0-96b4-cfe0b62a5c52/download https://repositorio.udes.edu.co/bitstreams/ff367075-e475-486d-8dac-db7047a71078/download https://repositorio.udes.edu.co/bitstreams/49ec4e25-e916-45e9-ab98-a84c0155a618/download |
| bitstream.checksum.fl_str_mv |
526654b88dc6627b529302b901cff673 0d190bb9222112adaf2512b82133b246 38d94cf55aa1bf2dac1a736ac45c881c b3614ae7d67b4ec406b1159bf6394a93 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Universidad de Santander |
| repository.mail.fl_str_mv |
soporte@metabiblioteca.com |
| _version_ |
1814158844912205824 |
| spelling |
Yusuf, Salim06a836b5-f5e3-41d9-a516-9cc46e5d7948-1Bosch, Jackie503f2202-0dda-463c-acc9-f5888e895278-1Dagenais, Gillesc865f015-4dc7-483d-9dae-132288d901f8-1Zhu, Jund97cdbd2-6a82-430c-abfe-c978f085997e-1Xavier, Denis88c9cf48-fa3b-45c6-be03-2cc79e59289d-1Liu, Lishenga14adafe-ef37-42b0-8f5b-0de4ea71b0fc-1Pais, Prem5abdbf77-3c3f-4396-8634-83723aa215b9-1Lopez-Jaramillo, Patricio9a71267b-dcb0-4d31-b37d-2d30be58d4d2-1Leiter, Lawrence A.bcdd3211-40b7-474d-9f6c-8a1051ceb9bf-1Dans, Antoniof365ef5a-7610-4022-8485-31d6d3879cd6-1Avezum, Alvaro8b920360-abb2-4ec8-b5ee-4e3f4e0b11eb-1Piegas, Leopoldo S.0f1da4dd-76bd-4381-87fa-1e01066eee6f-1Parkhomenko, Alexander11fab1ea-f0f6-47e0-97e9-36e372b7e2f9-1Keltai, Kataline6748cb0-125e-4199-9d27-8f14335aec02-1Keltai, Matyas65c5da4f-dca6-4e4f-aa9e-6c2ff81f2df9-1Sliwa, Karen7ff2b80f-9412-4d65-99cd-7d01d5578687-1Peters, Ron J.G.43007a97-9e31-41a5-a7fc-ce7357bd484f-1Held, Claes76b69ce8-c468-49c5-8d48-95a823d8b565-1Chazova, Irinace6fc484-15aa-401c-a370-8afcad931907-1Yusoff, Khalid933db13d-f5bb-4ea6-91a5-68eea1ca9ffc-1Lewis, Basil S.a8106b8e-2b4b-412e-90c7-4012b1272405-1Jansky, Petrbf8ec62a-6edc-439c-a698-2e4fa4172f04-1Khunti, Kamleshe9aff03a-6f97-433d-a56e-8d7f703caa03-1Toff, William D.97acb6df-c33b-45ad-b772-c52ac4aa7281-1Reid, Christopher M.7d8a8211-12ad-464c-948d-16952b66144d-1Varigos, Johnedec3b03-87c5-454c-aec5-b2c04c91a9d9-1Sánchez Vallejo, Gregorio7faafd42-5dfc-4314-95bf-9a4eb6469aeb-1McKelvie, Robertb7cfc72e-3a56-4797-8848-d0db71a3ef50-1Pogue, Janiceda5c963c-440a-4bf6-981a-f2217b50fc1d-1Jung, Hyejung50f4ceae-59e5-4f12-9788-b713f56de3be-1Gao, Peggy46954da1-6290-4040-9c8c-33dcfaf225dd-1Diaz, Rafaelf2be4a74-501a-4e63-8bbd-965cbcf8c57b-1Lonn, Eva7a977a4b-14e3-44cc-8057-933d424aaa9b-1The HOPE-3 Investigatorsad5cd98d-86e0-4739-a226-91ef50ed152c-12019-07-24T17:13:45Z2019-07-24T17:13:45Z2016-05-2611 p.BACKGROUND Previous trials have shown that the use of statins to lower cholesterol reduces the risk of cardiovascular events among persons without cardiovascular disease. Those trials have involved persons with elevated lipid levels or inflammatory markers and involved mainly white persons. It is unclear whether the benefits of statins can be extended to an intermediate-risk, ethnically diverse population without cardiovascular disease. METHODS In one comparison from a 2-by-2 factorial trial, we randomly assigned 12,705 participants in 21 countries who did not have cardiovascular disease and were at intermediate risk to receive rosuvastatin at a dose of 10 mg per day or placebo. The first coprimary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, and the second coprimary outcome additionally included revascularization, heart failure, and resuscitated cardiac arrest. The median follow-up was 5.6 years. RESULTS The overall mean low-density lipoprotein cholesterol level was 26.5% lower in the rosuvastatin group than in the placebo group. The first coprimary outcome occurred in 235 participants (3.7%) in the rosuvastatin group and in 304 participants (4.8%) in the placebo group (hazard ratio, 0.76; 95% confidence interval [CI], 0.64 to 0.91; P=0.002). The results for the second coprimary outcome were consistent with the results for the first (occurring in 277 participants [4.4%] in the rosuvastatin group and in 363 participants [5.7%] in the placebo group; hazard ratio, 0.75; 95% CI, 0.64 to 0.88; P<0.001). The results were also consistent in subgroups defined according to cardiovascular risk at baseline, lipid level, C-reactive protein level, blood pressure, and race or ethnic group. In the rosuvastatin group, there was no excess of diabetes or cancers, but there was an excess of cataract surgery (in 3.8% of the participants, vs. 3.1% in the placebo group; P=0.02) and muscle symptoms (in 5.8% of the participants, vs. 4.7% in the placebo group; P=0.005). CONCLUSIONS Treatment with rosuvastatin at a dose of 10 mg per day resulted in a significantly lower risk of cardiovascular events than placebo in an intermediate-risk, ethnically diverse population without cardiovascular disease. (Funded by the Canadian Institutes of Health Research and AstraZeneca; HOPE-3 ClinicalTrials.gov number, NCT00468923.application/pdf10.1056/NEJMoa16001761533-44060028-4793https://repositorio.udes.edu.co/handle/001/3459engNew England Journal of MedicineDerechos Reservados - New England Journal of Medicine, 2016info:eu-repo/semantics/openAccessAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)https://creativecommons.org/licenses/by-nc/4.0/http://purl.org/coar/access_right/c_abf2https://pdfs.semanticscholar.org/fd2d/366541ea99b1b518b789b4456c65fe2c9913.pdf?_ga=2.266816654.1207694793.1563984236-1782380525.1556661431Cholesterol loweringIntermediate riskCardiovascular diseaseCholesterol lowering in intermediate-risk persons without cardiovascular diseaseArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85PublicationTHUMBNAILCholesterol lowering in intermediate-risk persons without cardiovascular disease.pdf.jpgCholesterol lowering in intermediate-risk persons without cardiovascular disease.pdf.jpgGenerated Thumbnailimage/jpeg1693https://repositorio.udes.edu.co/bitstreams/6a604cda-8879-45a8-b62c-f0510a013e1f/download526654b88dc6627b529302b901cff673MD54TEXTCholesterol lowering in intermediate-risk persons without cardiovascular disease.pdf.txtCholesterol lowering in intermediate-risk persons without cardiovascular disease.pdf.txtExtracted texttext/plain48294https://repositorio.udes.edu.co/bitstreams/c1f0f371-7d30-41d0-96b4-cfe0b62a5c52/download0d190bb9222112adaf2512b82133b246MD53LICENSElicense.txtlicense.txttext/plain; charset=utf-859https://repositorio.udes.edu.co/bitstreams/ff367075-e475-486d-8dac-db7047a71078/download38d94cf55aa1bf2dac1a736ac45c881cMD52ORIGINALCholesterol lowering in intermediate-risk persons without cardiovascular disease.pdfCholesterol lowering in intermediate-risk persons without cardiovascular disease.pdfapplication/pdf297904https://repositorio.udes.edu.co/bitstreams/49ec4e25-e916-45e9-ab98-a84c0155a618/downloadb3614ae7d67b4ec406b1159bf6394a93MD55001/3459oai:repositorio.udes.edu.co:001/34592023-10-10 08:39:43.383https://creativecommons.org/licenses/by-nc/4.0/Derechos Reservados - New England Journal of Medicine, 2016https://repositorio.udes.edu.coRepositorio Universidad de Santandersoporte@metabiblioteca.comTGljZW5jaWEgZGUgUHVibGljYWNpw7NuIFVERVMKRGlyZWN0cmljZXMgZGUgVVNPIHkgQUNDRVNPCgo= |